Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.

Slides:

Advertisements

Similar presentations

David J. Hass, MD Assistant Clinical Professor of Medicine Yale University School of Medicine Gastroenterology Center of Connecticut, P.C.

Advertisements

AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.

Lower Gastrointestinal NET Clinical case One patient and how many doctors ? Dimitrios Dimitroulopoulos MD, PhD Consultant Gastroenterology Dpt. “Agios.

Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.

IMAGE CHALLENGE. A 51-year-old woman with a history of hypertension and chronic constipation presented with abdominal pain of 2 weeks' duration. The.

CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.

Martina Rastovac Mentor: A. Žmegač Horvat. Actor Patrick Swayze died after a 20-month battle with pancreatic cancer. He was 57.Patrick Swayze.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

Prepare by: Ahmad Rsheed Presented to: Fatima Harzallah

Management of GIST Dr Kwan Ming Wa Tuen Mun Hospital.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Moving Toward Personalized Treatment for Gastric Cancer: Role of HER2 Testing Frédérique Penault-Llorca, MD, PhD Professor of Pathology Centre Jean Perrin.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

Nurse Navigators and the Cancer Institute Yousuf A. Gaffar, MD Hematology / Medical Oncology The Cancer Institute University of Maryland St. Joseph Medical.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Living Beyond Breast Cancer Liver and Lung Metastases Workshop April 29, 2012 Paul B. Gilman, MDLankenau Medical Center.

Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”

Unit of Gastrenterology Unit of Endocrinology THEAGENIO Hospital, Thessaloniki Metastatic neuroendocrine tumor of the jejunum-ileum.

In the name of God Isfahan medical school Shahnaz Aram MD.

Digestive Disorders. Crohn’s Disease Chronic inflammatory bowel disease. Most common in small/large intestine. Causes: –Possible hereditary link to autoimmune.

Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Morganstein (Prof Van Cutsem) 78 yo woman with Stage IV GE adenocarcinoma.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

NYU Medical Grand Rounds Clinical Vignette Daniel P. Eiras, MD, MPH PGY2 December 1, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

PANCREATIC CANCER.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

Endocrinology Unit Pathophysiology Department Laikon General Hospital Case Presentation: Dr. Chatzellis Eleftherios MD Intern in Endocrinology.

Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.

Gastric Cancer Gidon Almogy MD Department of General Surgery Hadassah University Hospital.

Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.

A 58 years old man presents with melena. What would you ask him?

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,

Clinical Correlations The NYU Internal Medicine Blog A Daily Dose of Medicine

Hungarian Pancreatic Study Group – Magyar Hasnyálmirigy Munkacsoport Gábor Lakatos 09 november th Conference of the Hungarian & 2 nd Conference.

When you hear hoofbeats… Nancy Fuller, M.D. Nov 28, 2007.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.

Oncology 2016 Mark D. Browning, M.D. ’77 Thyroid & Gastric Cancer

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

Authors: Syed H. Jafri ¹, Angel I. Blanco¹, Bonnie A. Labdi², Shan Guo¹. UT Houston department of medicine, Division of Oncology Department of Pharmacy.

TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR TREATMENT OF HER2- POSITIVE ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

Case. Kreem is 53 year old man who is quite healthy with no previous illness. He has noticed changes in his bowel habits for the last few months, with.

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,

Stomach cancer.

SURGICAL ONCOLOGY AND TUMOR MARKERS

Short-term outcome of neo-adjuvant chemotherapy

Fig. 8. Response to aromatase inhibitor and cyclin dependent kinase inhibitor in metastatic hormone receptor+, HER2 negative breast cancer. In this 29-year-old.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

The Evolving Standard of Care in Gastric Cancer

GEMSTONE Educational Case Summary

Stephen Ansell, MD, PhD Mayo Clinic

GEMSTONE Educational Case Summary

Krop I et al. SABCS 2009;Abstract 5090.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

GEMSTONE Educational Case Summary

What is the role of genetic testing in patients with ovarian cancer?

Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma Anne.

STOMACH CANCER BY DR: ALI ALWAILY/MD.

GEMSTONE Educational Case Summary

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Fig. 4. Treatment algorithm for palliative systemic therapy

General strategies of Cancer Treatment and evaluation of Response

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Presentation transcript:

Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology Hospital Universitario Central de Asturias Oviedo, Spain

Patient History and Presentation of Disease Personal history: –46-year-old woman –No other relevant history Family history: –Paternal grandfather: stomach cancer (51 years old) –Maternal aunt: breast cancer (45 years old) Disease presentation: February 2008 –Decreased appetite, early satiety, weight loss, and vomiting

Diagnosis: Stage IV Adenocarcinoma of Stomach Gastroscopy: ulcerated lesion in antrum –Biopsy: poorly differentiated, diffuse adenocarcinoma CT scan and abdominal echography –Liver lesions: 2.1 and 0.7 cm Tumor markers: elevated CEA, CA 19.9 and CA 72.4 CA = carbohydrate antigen; CEA = carcinoembryonic antigen; CT= computed tomography

Treatment Surgical resection: April 2008 –Partial gastrectomy and left anexectomy –Miliary lesions in peritoneum, lesions in liver and left ovary Systemic therapy: May 2008 –Cycle 1–6: cisplatin 70 mg/m 2, capecitabine 850 mg/m 2 D1–14 Based on the literature: HER2 testing requested –HER2 test result: IHC 3+ Cycle 7–27: trastuzumab 6 mg/kg/q3w + capecitabine HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry

Tumor Assessment: Stable Disease at Cycle 3 Baseline: before treatment Cisplatin + capecitabine May 2008 Sep 2008 Imaging studies property of Jose Maria Vieitez, MD.

Tumor Assessment: Complete Response at Cycle 17 Trastuzumab + capecitabine Imaging studies property of Jose Maria Vieitez, MD.

Tumor Assessment: Disease Progression at Cycle 27 Trastuzumab + capecitabine Good quality of life and symptom relief Grade 1 anemia Grade 2 asthenia Grade 3 vomiting (responded to antiemetics) Time to progression: 17 months Jan 2010 Imaging studies property of Jose Maria Vieitez, MD.

Conclusions Treatment with trastuzumab is well tolerated, even in prolonged treatment Addition of trastuzumab in appropriately selected patients can increase efficacy, time to progression, and overall survival outside of clinical trial setting